Use access key #2 to skip to page content.
$0.51 -0.01 (-1.92%)
10/13/2008 2:39 PM

Cell Genesys, Inc. (CEGE)

CAPS Rating:
****

A biotechnology company focused on the development and commercialization of novel biological therapies for patients with cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

CEGE doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

254 Outperforms
24 Underperforms
 

All-Stars

27 Outperforms
8 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on CEGE are also bullish on:

Members bearish on CEGE are also bearish on:

Ticker Tags

Biotechnology (295), Rule Breakers Universe (161), Micro Cap (4824)
Suggest a tag

Cell Genesys, Inc. At A Glance

Current Price: $0.51
Last Trade Time: 10/13/2008 2:39 PM
Open: $0.56
Previous Close: $0.52
Daily Range: $0.43 - $0.56
52-Week Range: $0.42 - $4.67
Volume: 593,512
Market Cap: $44.67M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CEGE VS S&P 500 (SPY)

CEGE 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for CEGE

More Headlines...

Top Bull Pitch

Recs

2

Cell Genesys, Inc. (CEGE)

Avatar cardinals18 (23.96) Submitted: 3/24/08 11:25 AM

Will get a partner deal done soon, also expect great news comming out of trials.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Cell Genesys, Inc. (CEGE)

Avatar mamicro (< 20) Submitted: 10/17/07 3:54 PM

It needs some good news to break out. The trials are't far enough along.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 56 :   1 2 3 4 5 Next » Jump to page:

Show Pitch Replies

Recs

0

 (CEGE)

Avatar Stampede1253 (< 20) Submitted: 8/14/08 7:52 PM : Outperform Start Price: $3.38 CEGE Score: -58.38

GVAX is on track with two phase III studies due to be released in second half of 2009. The Takeda deal only solidified a solid platform for GVAX and the desired endpoint of extended life.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CEGE)

Avatar mattjetfan (< 20) Submitted: 8/11/08 11:53 PM : Outperform Start Price: $3.09 CEGE Score: -56.73

NIce stock. Very Very Volatile, hopefully will continue to climb.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CEGE)

Avatar ks4rate (< 20) Submitted: 7/10/08 10:16 AM : Outperform Start Price: $2.50 CEGE Score: -56.62

New developments and improvement.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CEGE)

Avatar RhoWidget (< 20) Submitted: 5/11/08 9:23 AM : Outperform Start Price: $3.98 CEGE Score: -55.77

FDA approval for GVAX by 2nd quarter CY09.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CEGE)

Avatar Money2themax (65.49) Submitted: 5/07/08 12:28 AM : Underperform Start Price: $3.74 CEGE Score: 53.62

IF full FDA approval happens for the cancer-fighting drug that is currently in Stage III Trials, this stock launches and never looks back! However, FDA approval timing is unpredictable so look for this stock to be in the doldrums for awhile yet.

Report this Post Replies: 2 | Reply | Permalink

Results 1 - 5 of 56 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackEveillard 83.35 09/30/07 Outperform NS $3.82-86.42%-37.21%-49.21 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners